Clinical Trial Update: EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

This document provides an update on a Phase 1 trial evaluating EMD 521873 in combination with radiotherapy for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EMD 521873

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Lung Cancer, Non Small Cell Lung Cancer | Phase 1 | Status: COMPLETED